Dr. Peter Gough offers a detailed regulatory overview addressing two critical issues in the pharmaceutical sector: artificial intelligence (AI) and drug shortages. He clarifies the current regulatory landscape in the EU, USA, and UK while forecasting future developments in these rapidly evolving areas.
Focusing on AI, Dr. Gough emphasizes its vast potential alongside inherent risks, echoing concerns from industry leaders about the necessity for stringent oversight. He highlights the EU as a frontrunner in AI legislation, having introduced Regulation 2024/1689, which outlines a phased implementation process extending to 2027. This regulation mandates organizations to comprehend applicable rules and their timelines, while the European Medicines Agency (EMA) reinforces the importance of safe data practices and continuous monitoring in AI applications.
On the topic of drug shortages, Dr. Gough identifies this as a significant global issue affecting patient care, citing specific shortages in hormone replacement therapy and oncology drugs. He reviews the evolution of U.S. regulatory responses, initiated by crises like the Ben Venue incident, which led to enhanced FDA oversight and expectations for proactive shortage management from manufacturers. In the EU, new legislation has expanded the EMA's role in monitoring shortages, including the launch of the European Shortages Monitoring Platform in February 2025, aimed at addressing supply chain vulnerabilities.
Dr. Gough concludes by stressing that resolving challenges related to AI governance and drug shortages requires collaborative efforts from both regulators and the industry. He advocates for a transparent, innovative approach focused on patient safety as regulatory frameworks continue to evolve.